???global.info.a_carregar???
I am Dr. Cristina Maria Godinho Pires João, a seasoned hematologist currently practicing and conducting research at the Champalimaud Foundation since 2015. I earned my PhD in Medicine from Universidade Nova de Lisboa, Faculty of Medical Sciences, graduating with laude, praise, and distinction in 2008. My Degree in Medicine was obtained from Universidade de Lisboa, Faculty of Medicine, in 1996. I pursued doctoral studies and a master's in clinical research at Mayo Clinic, Rochester, MN, USA, from 2002 to 2006. Specializing in Clinical Hematology in 2008, I achieved a final classification of 19.9 out of 20. Since 2010, I have served as a tenured assistant professor of Immunology at the Faculty of Medical Sciences of Universidade Nova de Lisboa. I have authored 75 articles in specialized journals, accumulating over 800 citations in the last six years. I have supervised two doctoral theses, co-supervised one, and overseen three master's dissertations. Currently advising three doctoral students and one master's student, I lead the research group on Lymphomas and Multiple Myeloma at the Champalimaud Foundation. My current scientific endeavors focus on translational research in Hemato-Oncology, particularly in Multiple Myeloma. My research interests revolve around understanding the immune microenvironment of Multiple Myeloma (MM) and leveraging fundamental immunological concepts for clinical applications in hematological malignancies. My research spans from investigating the role of B cells and immunoglobulins in T cell development to exploring liquid biopsies as biomarkers in MM progression. I am also engaged in multi-omics approaches to elucidate MM aggressiveness and am developing a project integrating genomics, proteomics, and radiomics data. As principal investigator of several academic clinical trials and serving as PI in pharmaceutical company-sponsored trials, I am an active member of various professional societies, including the Portuguese Multiple Myeloma Group, the Portuguese Lymphoma Group, the International Working Group of Multiple Myeloma (IMWG), the Portuguese Society of Hematology, the European Society of Hematology, EATRIS (European Infrastructure for Translational Medicine), and EuROFLOW. I contribute my expertise to several IMWG working groups and have received nine prizes and/or honors for my contributions to the field.
Identificação

Identificação pessoal

Nome completo
Cristina Maria Godinho Pires João

Nomes de citação

  • Cristina João

Identificadores de autor

Ciência ID
F812-814B-AEED
ORCID iD
0000-0002-3978-766X

Endereços de correio eletrónico

  • cristina.joao@fundacaochampalimaud.pt (Profissional)
  • cristina.joao@research.fchampalimaud.org (Profissional)
  • cristina.joao@research.fchampalimaud.org (Pessoal)

Moradas

  • Fundação Champalimaud. Av Brasilia, 1044, Lisboa, Lisboa, Portugal (Profissional)

Websites

Domínios de atuação

  • Ciências Médicas e da Saúde - Medicina Clínica - Hematologia
  • Ciências Médicas e da Saúde - Medicina Básica - Imunologia
  • Ciências Médicas e da Saúde - Medicina Clínica - Oncologia
  • Ciências Médicas e da Saúde - Medicina Clínica - Outras Áreas da Medicina Clínica

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Inglês Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Francês Utilizador elementar (A1) Utilizador independente (B1) Utilizador elementar (A1) Utilizador elementar (A1)
Português Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Espanhol; Castelhano Utilizador independente (B1) Utilizador independente (B1) Utilizador elementar (A1) Utilizador independente (B1)
Formação
Grau Classificação
2008/02/22 - 2018/08/14
Concluído
Consultant Degree in Clinical Hematology (Outros)
Especialização em Clinical Hematology
ACSS- Administração Central do Sistema de Saude, Portugal
17/20
2008/03/04
Concluído
Master's in Biomedical Sciences, Clinical Investigation (Mestrado integrado)
Especialização em Master's in Biomedical Sciences, Clinical Investigation
Universidade Nova de Lisboa, Portugal
"B cell dependent T cell development" (TESE/DISSERTAÇÃO)
Approved
1998/01/02 - 2008/02/22
Concluído
Clinical Hematology Specialist (Título de especialista)
Especialização em Clinical Hematology
Ordem dos Médicos, Portugal
19,9/20
2008
Concluído
Medicine (Doutoramento)
Especialização em Specialty: Internal Medicine
Universidade NOVA de Lisboa NOVA Medical School, Portugal
"Reconstituição do Reportório Imunológico em Contexto de Transplantação Hematopoiética / Reconstitution of the Immunological Repertoire in the Context of Hematopoietic Transplantation" (TESE/DISSERTAÇÃO)
2004 - 2006
Concluído
Master in Clinical Research (Master)
Especialização em Investigação Clinica
Mayo Clinic Cancer Center, Estados Unidos
"B cell dependent T cell development" (TESE/DISSERTAÇÃO)
Excelent
1997 - 1997
Concluído
Ensino prático - como fazer, como avaliar? / Practical teaching - how to do it, how to evaluate it? (Especialização pós-licenciatura)
Especialização em Medical Education
Universidade de Lisboa Faculdade de Medicina, Portugal
Apta
1997 - 1997
Concluído
Advances in Immunology (Especialização pós-licenciatura)
Especialização em Imunologia
Instituto Gulbenkian de Ciência, Portugal
Apta
1996/07 - 1996/08
Concluído
The 1st Copenhagen International Interdisciplinary School in Biological Science: "The spontaneous order of life - in search of the loss of self-organization in Physical, Biological and Cognitive Systems" (Postgraduate Certificate)
Especialização em Biological Systems
Københavns Universitet Niels Bohr Instituttet, Dinamarca
Pass
1990/09 - 1996/07/22
Concluído
Medicine (Licenciatura)
Universidade de Lisboa Faculdade de Medicina, Portugal
18/20
Percurso profissional

Docência no Ensino Superior

Categoria Profissional
Instituição de acolhimento
Empregador
2010/02/01 - Atual Professor Auxiliar Convidado (Docente Universitário) Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2016/09/01 - 2021/07/31 Leitor (Docente Universitário) Centro Hospitalar e Universitario de Coimbra EPE Campus dos Hospitais da Universidade de Coimbra, Portugal
Centro Hospitalar e Universitario de Coimbra EPE Campus dos Hospitais da Universidade de Coimbra, Portugal
2019/10/14 - 2019/10/16 Leitor (Docente Universitário) Sociedade Portuguesa de Hematologia, Portugal
Sociedade Portuguesa de Hematologia, Portugal
2016 - 2016 Professor Visitante (Docente Universitário) Janssen Pharmaceuticals Inc, Hungria
Janssen Pharmaceuticals Inc, Hungria
2011/09/01 - 2012/06/30 Assistente Convidado (Docente Universitário) Université Sorbonne Paris Nord UFR de Santé Médecine Biologie Humaine, França
Université Sorbonne Paris Nord UFR de Santé Médecine Biologie Humaine, França
2007/10/01 - 2008/03/31 Professor Associado Convidado (Docente Universitário) Universidade de Lisboa Instituto de Medicina Preventiva e Saúde Pública, Portugal
Universidade de Lisboa Instituto de Medicina Preventiva e Saúde Pública, Portugal
(...)

Cargos e Funções

Categoria Profissional
Instituição de acolhimento
Empregador
2023/11/01 - Atual Directors Board member of EuroFlow EuroFlow, Países Baixos
2023/11/01 - Atual Assembly secretary Sociedade Portuguesa de Hematologia, Portugal
2021/12/01 - Atual Directors Board member of the Multiple Myeloma Group Sociedade Portuguesa de Hematologia, Portugal
2019 - Atual Research Group Leader Fundação Champalimaud, Portugal
2018/08/14 - Atual Hematologist Consultant Fundação Champalimaud, Portugal
2015/01/01 - Atual Member of the Bone and Imaging Working Committee International Myeloma Foundation, Estados Unidos
International Myeloma Working Group, Estados Unidos
2015/01/01 - Atual Member of the Smouldering Multiple Myeloma Working Committee International Myeloma Foundation, Estados Unidos
International Myeloma Working Group, Estados Unidos

Outros

Categoria Profissional
Instituição de acolhimento
Empregador
2008/04/01 - 2015/05/01 Hematology Assistant (clinical responsabilities at the Hematology Department, IPO Lisboa) Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
2008/01/01 - 2015/05/01 Researcher (Principal Investigator, Scientific Research on Immune Reconstitution) Instituto Português de Oncologia de Lisboa Francisco Gentil EPE Unidade de Investigação em Patobiologia Molecular, Portugal
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE Unidade de Investigação em Patobiologia Molecular, Portugal
2009 - 2014 Principal Investigator Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal
2006/06/01 - 2010/01/01 External Research Collaborator Mayo Clinic Cancer Center, Estados Unidos
1999/01/01 - 2008/03/01 Resident in Clinical Hematology (interrupted to PhD studies between 2003 and 2006) Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
2006 - 2008 Research Collaborator Instituto Gulbenkian de Ciência, Portugal
2005 - 2006 External Post doctoral Research Fellow Mayo Clinic Cancer Center, Estados Unidos
2002/06 - 2005 Post doctoral Research Fellow Mayo Clinic Cancer Center, Estados Unidos
1997/01/01 - 1998/12/31 General Residency Hospital Distrital De Santarém Epe, Portugal
1995/09/01 - 1997/07/01 Hired assistant of Histology and Embriology Universidade de Lisboa Faculdade de Medicina, Portugal
Projetos

Bolsa

Designação Financiadores
2022/10/02 - 2024/06/30 Study of the neuronal role on the interplay between NK cells and Multiple Myeloma (NeuriMM)
Study of the neuronal role on the interplay between NK cells and Multiple Myeloma (NeuriMM)
Investigador responsável
Fundação Champalimaud, Portugal
Associação Portuguesa Contra a Leucemia

Sociedade Portuguesa de Hematologia

Amgen - Bio - Farmacêutica, Lda
Em curso
2009/01 - 2012/06 Lupus and its compensation in unaffected relatives by T-cell regulation
Investigador
Fundação para a Ciência e a Tecnologia
Concluído
2010 - 2011 Assessment of T cell receptor diversity in different imbalance immunological conditions using CDR3 spectratyping
FCT_ProgramaPessoa2010
Investigador responsável
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE Unidade de Investigação em Patobiologia Molecular, Portugal

Instituto Gulbenkian de Ciência, Portugal

Sorbonne Université Faculté de Médecine Campus Pitié-Salpêtrière, França
Fundação para a Ciência e a Tecnologia
Concluído
2007 - 2011 B cell modulation of T cells function and repertoire - immune characterization of lymphoma patients receiving chemotherapy with or without a B cell depleting agent, Rituximab
APCL2007
Investigador responsável
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE Unidade de Investigação em Patobiologia Molecular, Portugal
Associação Portuguesa contra a Leucemia
Concluído
2007/09 - 2010/12 Quantitative and Qualitative T cell receptor repertoire requirements for immune tolerance establishment and maintenance
Investigador
Fundação para a Ciência e a Tecnologia
2002/07/01 - 2006/05/31 B cell-dependent T cell development and function
SFRH/BD/6797/2001
Universidade NOVA de Lisboa NOVA Medical School, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2002 - 2006 Immune reconstitution after bone marrow transplantation
SFRH/BD/6797/2001
Bolseiro de Doutoramento
Fundação para a Ciência e a Tecnologia, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2001 - 2002 Cytogenetic abnormalities in MALT lymphomas
GHOP_MALT Lymphomas2001
Investigador responsável
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
GHOP – Portuguese Group of Onco-Hematology Fellowship
Concluído

Projeto

Designação Financiadores
2020/11/25 - Atual Exploring the bone marrow microenvironment communication via extracellular vesicles in an immunocompetent multiple myeloma mouse models and its potential translation to human disease
Refª - PGG/058/2019
Refª - PGG/058/2019
Investigador responsável
Fundação Champalimaud, Portugal
Gilead Sciences Lda
Concluído
2019/07 - Atual LyRaCAD (Sistema CAD para análise de imagens PET/CT com 18F-FDG em linfomas – uma abordagem radiomics)
POCI-01-0247-FEDER-039885
Investigador
Fundação Champalimaud, Portugal
Horizon 2020
Em curso
2019 - Atual Zebrafish avatar for CLL therapy screening
Kickstarters 2019
Fundação Champalimaud, Portugal
Fundação Champalimaud
Em curso
2017 - Atual The role of metastatic microenvironment in Multiple Myeloma extramedullary disease (EMphAsIS)
PTDC/MEC-HEM/30315/2017
Fundação Champalimaud, Portugal
Em curso
2015 - Atual Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects with Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma
CC-5013-DLC-002
CC-5013-DLC-002
Investigador
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
Celgene Portugal
Em curso
2023/11/01 - 2025/10/31 Identification of non-invasive genetic biomarkers predicting Daratumumab plus carfilzomib and dexamethasone response in Multiple Myeloma
IIS RESEARCH SUPPORT APPLICATION INVESTIGATOR-INITIATED STUDY
Co-Investigador Responsável (Co-IR)
Fundação Champalimaud, Portugal
Janssen Global Services LLC
Em curso
2022/01/01 - 2024/12/31 Unic.MM: Combined immunotherapy as a strategy for manipulating the bone marrow microenvironment in multiple myeloma
PTDC/MED-ONC/1215/2021
Investigador responsável
Fundação Champalimaud, Portugal

Universidade Nova de Lisboa, Portugal

Universidade Nova de Lisboa Centro de Toxicogenómica e Saúde Humana, Portugal

Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2016/11/04 - 2023/03/10 TOURMALINE - A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/¿or Refractory Multiple Myeloma
Investigador responsável
Fundação Champalimaud, Portugal

Takeda Global Research and Development Center Inc, Estados Unidos
Takeda Global Research and Development Center Inc
Concluído
2018/12/03 - 2022/07/01 EMphAsIS_The role of metastatic microenvironment in Multiple Myeloma extramedullary disease.
FCT-PTDC/MEC-HEM/30315/2017
PTDC/MEC-HEM/30315/2017
PTDC/MEC-HEM/30315/2017
Investigador responsável
Fundação Champalimaud, Portugal
Fundação para a Ciência e a Tecnologia

N/A
Em curso
2021/01/28 - 2021/03/10 Study of the neuronal role on the interplay between NK cells and Multiple Myeloma (NeuriMM)
2022.08762.PTDC
Investigador
Fundação Champalimaud, Portugal
Fundação para a Ciência e a Tecnologia
Em curso
2016 - 2018 Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
Investigador responsável
Fundação Champalimaud, Portugal
Takeda Farmacêuticos Portugal
Concluído
2013 - 2015 Open-label study with Pomalidomide in Combination with Low Dose Dexamethasone in subjects with Refractory or Relapsed and Refractory Multiple Myeloma
CC-4047-MM-010
Investigador responsável
Celgene Portugal, Portugal
Celgene Portugal
Concluído
2013 - 2015 A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton’s Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Who Have Received At least One Prior Therapy
NCT01646021
Investigador responsável
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
Janssen-Cilag Farmacêutica Lda
Concluído
2011/03/15 - 2014/09/14 Chronic intermittent eucapnic hypoxia: systemic effects and assessment of the efficacy of antihypertensive drugs
PTDC/SAU-TOX/112264/2009
Universidade NOVA de Lisboa NOVA Medical School, Portugal

Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal

Universidad de Valladolid, Espanha

Instituto de Biologia Experimental e Tecnológica, Portugal

Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2010 - 2014 Randomized phase IIIb clinical trial of Mabthera (Rituximab) added to chemotherapy, Bendamustine or Chlorambucil, in patients with Chronic Lymphocytic Leukemia
MO22468
Investigador responsável
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
Roche Farmaceutica Quimica Lda
Concluído
2010 - 2013 Chronic Intermittent Eucapnic Hypoxia: systemic effects and evaluation of anti-hypertensive drugs efficacy
PTDC/SAL-TOX/112264/2009
Investigador
Fundação para a Ciência e a Tecnologia, Portugal

Universidade Nova de Lisboa Centro de Estudos de Doenças Crónicas, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2009/01/01 - 2012/06/30 Lupus and its compensation in unaffected relatives by T cell regulation
PIC/IC/82746/2007
Fundação Calouste Gulbenkian, Portugal

Instituto Gulbenkian de Ciência, Portugal

Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Associacao de Doentes com Lupus, Portugal

Hospital Geral de Santo António SA, Portugal

Universidade de Trás-os-Montes e Alto Douro Centro de Investigação e de Tecnologias Agro-Ambientais e Biologicas, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2007/09/01 - 2010/12/31 Repertoire of T cell receptors in the generation and maintenance of immunological tolerance: Qualitative and quantitative requirements.
PTDC/SAU-MII/71402/2006
Investigador
Fundação Calouste Gulbenkian, Portugal

Instituto Gulbenkian de Ciência, Portugal

Universidade de Trás-os-Montes e Alto Douro Centro de Investigação e de Tecnologias Agro-Ambientais e Biologicas, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2007/09/01 - 2010/08/31 Immune reconstitution after Autologous Hematopoietic Stem Cell Transplantation - modulation by immunoglobulins and potential clinical application
PTDC/SAU-MII/65029/2006
Investigador responsável
Fundação Calouste Gulbenkian, Portugal

Instituto Gulbenkian de Ciência, Portugal

Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal

Universidade de Trás-os-Montes e Alto Douro Centro de Investigação e de Tecnologias Agro-Ambientais e Biologicas, Portugal

Institut Pasteur, França
Fundação para a Ciência e a Tecnologia
Concluído
2007 - 2010 Lupus and its compensation in unaffected relatives by T-cell regulation
PIC/IC/82746/2007
Investigador
Fundação para a Ciência e a Tecnologia, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
2007/09/01 - 2009 Immune recovery after Autologous Stem Cell Transplantation - modulation by Ig and potential clinical application
2006-30.4M.AP/MJ
PTDC/SAU-MII/65029/2006
Investigador responsável
Associação Portuguesa contra a Leucemia, Portugal

Fundação para a Ciência e a Tecnologia, Portugal
Associação Portuguesa contra a Leucemia

Fundação para a Ciência e a Tecnologia
Concluído

Outro

Designação Financiadores
2023/01/23 - Atual VOLTA project
Desenvolvimento técnico
2023/01/01 - Atual CarMMa - Characterization of the Population of Patients with Multiple Myeloma Treated in Portuguese Hospitals and Characterization of Their Caregivers
CarMMa
Investigador responsável
Em curso
2023/06/02 - 2033/11/30 SUCCESSOR-1 - A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Investigador responsável
Fundação Champalimaud, Portugal

Celgene, Estados Unidos
Celgene
Em curso
2022/10/17 - 2032/06/25 EXCALIBER-RRMM - Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Investigador responsável
Celgene, Estados Unidos

Fundação Champalimaud, Portugal
Celgene
Em curso
2023/07/28 - 2031/08/31 MajesTEC-9 - A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Investigador responsável
Janssen Research & Development, LLC, Estados Unidos

Fundação Champalimaud, Portugal
Janssen Research & Development, LLC
Em curso
2023/03/03 - 2027/04/06 MK-2140-006 - A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies
Investigador responsável
Fundação Champalimaud, Portugal

Merck Sharp & Dohme Corp, Estados Unidos
Merck Sharp & Dohme Corp
2021/12/03 - 2027/02/05 ESCALADE - A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Investigador responsável
AstraZeneca Pharmaceuticals LP, Estados Unidos

Fundação Champalimaud, Portugal
AstraZeneca Pharmaceuticals LP
Em curso
2021/11/12 - 2026/11/01 CONPET - Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
Investigador responsável
Oslo universitetssykehus, Noruega

Fundação Champalimaud, Portugal
Oslo universitetssykehus
2023/04/14 - 2026/04/27 IMPACTMF - A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Investigador responsável
Geron Corporation, Estados Unidos

Fundação Champalimaud, Portugal
Geron Corporation
Em curso
2021/10/26 - 2025/04/01 LOXO-BRUIN - Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)
Investigador responsável
Loxo Oncology Inc, Estados Unidos

Fundação Champalimaud, Portugal
Loxo Oncology Inc
Em curso
2023/10/17 - 2024/07/17 ACT17453 - A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Investigador responsável
Fundação Champalimaud, Portugal

Sanofi SA Research and Development Waltham, Estados Unidos
Sanofi SA Research and Development Waltham
Em curso
2021/08/17 - 2023/12/29 CAS-OFLYRICLB - Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer
Investigador
Fundação Champalimaud, Portugal

Becton, Dickinson and Company, Estados Unidos
Becton, Dickinson and Company
Desativado
2022/07/29 - 2023/11/07 KRT232-101_BOREAS - KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Investigador responsável
Kartos Therapeutics, Inc., Estados Unidos

Fundação Champalimaud, Portugal
Kartos Therapeutics, Inc.
Concluído
2021/10/22 - 2023/10/25 CAS-OFLYRICPP - Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer
Investigador
Becton, Dickinson and Company, Estados Unidos

Fundação Champalimaud, Portugal
Becton, Dickinson and Company
Concluído
2015/11/16 - 2023/10/04 ALCYONE - A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Investigador responsável
Fundação Champalimaud, Portugal

Janssen Research and Development Belgium Discovery Process Research Group, Bélgica
Janssen Research and Development Belgium Discovery Process Research Group
Em curso
2022/12/06 - 2023/09/01 CAS-OFLBT1T4 - BD OneFlow CLPD Panel (BD OneFlow LST and B-CLPD assays T1 to T4) in the BD FACSLyric System.
Investigador
Fundação Champalimaud, Portugal

Becton Dickinson and Company, Estados Unidos
Becton Dickinson and Company
Em curso
2022/07/29 - 2023/06/30 KRT232-111 - Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Investigador responsável
Fundação Champalimaud, Portugal

Kartos Therapeutics, Inc., Estados Unidos
Kartos Therapeutics, Inc.
Concluído
2021/03/09 - 2023/04/28 MRDeep - Prevalence of minimal residual disease (MRD) in patients treated for Multiple Myeloma (MM) who reach complete response and are currently on 2nd or 3rd line of therapy for MM
MRDEEP
Investigador responsável
Janssen Global Services LLC, Estados Unidos

Fundação Champalimaud, Portugal
Janssen Global Services LLC
2020/05/04 - 2023/04/17 FIRST-MIND - Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
Investigador responsável
Fundação Champalimaud, Portugal

MorphoSys AG, Alemanha
MorphoSys AG
Concluído
2021/09/10 - 2023/01/30 ENHANCE - Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL
Investigador responsável
Cornell University Joan and Sanford I Weill Medical College, Estados Unidos

Fundação Champalimaud, Portugal
Cornell University Joan and Sanford I Weill Medical College
Concluído
2019/08/02 - 2022/12/19 EMN23/54767414AMY0001 - A Retrospective Observational Multicenter Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe
Investigador responsável
European Myeloma Network, Países Baixos

Fundação Champalimaud, Portugal
European Myeloma Network
Concluído
2017/09/01 - 2018/08/31 Atlas-based semi-automatic segmentation of Whole-Body DWI Images: Quantification of tumour burden
Kickstarter
Investigador responsável
Fundação Champalimaud, Portugal
Fundação Champalimaud
Concluído
Produções

Publicações

Artigo em conferência
  1. Cláudia S. Constantino; Oliveira, Francisco; Sónia Leocádio; Mariana Silva; Carla Oliveira; Joana C. Castanheira; Ângelo Silva; et al. "A robust deep-learning model for fully automatic segmentation of lymphoma lesions on whole-body [18F]FDG PET/CT images". Trabalho apresentado em IEEE International Symposium on Biomedical Imaging, 2024.
    Aceite para publicação
  2. Velosa Ferreira, Bruna; Ana Filipa Barahona Afonso; Pestana, Carolina; Ana Raquel lopes; Matthiesen, Rune; Caetano, Joana. "Extrecellular vesicle proteins as biomarker of outcome in multiple myeloma patients: a real world study". Trabalho apresentado em Perspectivas em Oncologia, Porto, 2022.
    Publicado
  3. Cristina João. "O tratamento com imunoglobulina ou fragmentos da molécula após transplante de precursores hematopoiéticos aumenta a proliferação celular à periferia". Trabalho apresentado em Annual Meeting of the Portuguese Society of Hematology 2008, torres vedras, 2008.
    Publicado
  4. Cristina João. "Treatment with polyclonal immunoglobulin and its fragments optimize recovery of IgM serum levels after autologous stem cells transplantation (ASCT)". Trabalho apresentado em Annual Meeting of Portuguese Society of Immunology 2007, lisboa, 2007.
  5. Cristina João. "Efeito da infusão de imunoglobulina ou seus derivados sobre a reconstituição imunológica após transplante autólogo de precursores hematopoiéticos (TAPH) num modelo animal (ratinho)". Trabalho apresentado em Annual Meeting Portuguese Society of Hematology 2007, Albufeira, 2007.
    Publicado
  6. João, Cristina; Matias T; Sá J.. "Paget’s Bone Disease associated with Myelofibrosis with Myeloid Metaplasiac". Trabalho apresentado em 6th National Congress of Internal Medicine, porto, 2000.
    Publicado
  7. João, Cristina; Silva, M.,; Nolasco I; Cabeçacas J; Parreira A. "Review of 6 cases of Kikushi-Fujimoto Disease from the Hematology Department of Francisco Gentil Portuguese Oncology Institute, Lisbon". Trabalho apresentado em Portuguese Hematology Society Annual Meeting 1999, Estoril, 1999.
    Publicado
Artigo em jornal
  1. Cristina João. "Notes on Multiple Myeloma, a type of blood cancer", Raio-X , 2022, https://raiox.pt/notas-sobre-mieloma-multiplo-um-tipo-de-cancro-do-sangue/.
Artigo em revista
  1. Jaccard, Arnaud; Bridoux, Frank; Roeloffzen, Wilfried; Minnema, Monique C.; Bergantim, Rui; Hájek, Roman; João, Cristina; et al. "Healthcare resource utilization and cost-of-illness in systemic light chain (AL) amyloidosis in Europe: results from the real-world, retrospective EMN23 study". Clinical Lymphoma Myeloma and Leukemia (2024): http://dx.doi.org/10.1016/j.clml.2024.01.013.
    Acesso aberto • No prelo • 10.1016/j.clml.2024.01.013
  2. Costa, Carlos BT; Neves, Manuel; Roque, Adriana Isabel; Sarmento-Ribeiro, Ana Bela; Gerivaz, Rita; Tomé, Ana; Afonso, Sofia; et al. "Assessment of Multiple Myeloma-Related Burden on Caregivers - a Portuguese National Study". Blood 142 Supplement (2023): 3335-3335. http://dx.doi.org/10.1182/blood-2023-182698.
    10.1182/blood-2023-182698
  3. Nørgaard, Jakob Nordberg; Abildgaard, Niels; Lysén, Anna; Tsykunova, Galina; Vangsted, Annette Juul; João, Cristina; Remen, Nora; et al. "Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation". Leukemia 37 10 (2023): 2107-2114. http://dx.doi.org/10.1038/s41375-023-01998-7.
    10.1038/s41375-023-01998-7
  4. Filipa Barahona, Ana; Klein Wolterink, Roel; Galzerano, Antonio; Carneiro, Emilie; Caetano, Joana; Velosa Ferreira, Bruna; Queirós, Ana; João, Cristina. "P837: High-dimensional spectral cytometry characterization of the circulating immune cell profile in asymptomatic and symptomatic myeloma patients". HemaSphere 7 S3 (2023): e777065e. http://dx.doi.org/10.1097/01.hs9.0000970252.77706.5e.
    Publicado • 10.1097/01.hs9.0000970252.77706.5e
  5. Caetano, Joana; Barahona, Filipa; Neves, Manuel; Velosa Ferreira, Bruna; Leocádio, Sónia; Queirós, Ana; Lúcio, Paulo; João, Cristina. "P821: High-dimensional spectral cytometry characterization of the circulating immune cell profile in asymptomatic and symptomatic myeloma patients". HemaSphere 7 S3 (2023): e54601b9. http://dx.doi.org/10.1097/01.hs9.0000970188.54601.b9.
    Publicado • 10.1097/01.hs9.0000970188.54601.b9
  6. João, Cristina; Bergantim, Rui; Santos, Joana; Afonso, Celina; Bernardo, Paulo; Coelho, Henrique; Costa, Carlos; et al. "Recommendations from the Portuguese Multiple Myeloma Group for the Treatment of Multiple Myeloma". Acta Médica Portuguesa 36 7-8 (2023): 517-526. http://dx.doi.org/10.20344/amp.19037.
    10.20344/amp.19037
  7. João, Cristina; Bergantim, Rui; Santos, Joana; Afonso, Celina; Bernardo, Paulo; Coelho, Henrique; Costa, Carlos; et al. "Recomendações do Grupo Português do Mieloma Múltiplo para Tratamento do Mieloma Múltiplo". Acta Médica Portuguesa 36 7-8 (2023): 517-526. http://dx.doi.org/10.20344/amp.19037.
    10.20344/amp.19037
  8. Constantino, Cláudia S.; Leocádio, Sónia; Oliveira, Francisco P. M.; Silva, Mariana; Oliveira, Carla; Castanheira, Joana C.; Silva, Ângelo; et al. "Evaluation of Semiautomatic and Deep Learning–Based Fully Automatic Segmentation Methods on [18F]FDG PET/CT Images from Patients with Lymphoma: Influence on Tumor Characterization". Journal of Digital Imaging 36 4 (2023): 1864-1876. http://dx.doi.org/10.1007/s10278-023-00823-y.
    10.1007/s10278-023-00823-y
  9. Cristina João. "World Health Day - Multiple Myeloma". Revista Business Portugal (2023): https://issuu.com/revistabusinessportugal/docs/rbp_marco_2023-online.
  10. Cristina João. "Everything you need to know about Multiple Myeloma". Sapo Lifestyle - Saúde e Medicina (2023): https://lifestyle.sapo.pt/saude/saude-e-medicina/artigos/tudo-o-que-precisa-de-saber-sobre-o-mieloma-multiplo.
  11. Palladini, Giovanni; Schönland, Stefan; Merlini, Giampaolo; Milani, Paolo; Jaccard, Arnaud; Bridoux, Frank; Dimopoulos, Meletios A.; et al. "The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018". Blood Cancer Journal 13 1 (2023): http://dx.doi.org/10.1038/s41408-023-00789-8.
    10.1038/s41408-023-00789-8
  12. Helena Sousa; Lara Cunha; Isabel Barbosa; Sergio Chacim; Ana Francisco; Joana Tato; Cristina João. Autor correspondente: Cristina João. "Living with multiple myeloma: Impact of the disease on patients' life in Portugal". Healthcare (2023):
    Submetido
  13. Fernanda Braga Seganfredo; Ana Raquel Dias; Pedro R. Santos; Marta Rebelo; Cristina João; Dina Mendes; Eduarda Carmo. "Successful treatment of persistent and severe SARS-CoV-2 infection in a high-risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies". Clinical Case Reports (2022): https://doi.org/10.1002/ccr3.6548.
    10.1002/ccr3.6548
  14. Diana Lourenço; Raquel Lopes; Carolina Pestana; Ana C. Queirós; Cristina João; Emilie Arnault Carneiro. "Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine—Are We There Yet?". International Journal of Molecular Sciences (2022): https://doi.org/10.3390/ijms232112888.
    10.3390/ijms232112888
  15. Lopes, Raquel; Caetano, Joana; Barahona, Filipa; Pestana, Carolina; Ferreira, Bruna Velosa; Lourenço, Diana; Queirós, Ana C.; et al. "Multiple Myeloma-Derived Extracellular Vesicles Modulate the Bone Marrow Immune Microenvironment". Frontiers in Immunology 13 (2022): http://dx.doi.org/10.3389/fimmu.2022.909880.
    Publicado • 10.3389/fimmu.2022.909880
  16. Joana Caetano; Filipa Barahona; Paulo Lúcio; Cristina João. "Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?". Hemato 3 3 (2022): 385-413. https://doi.org/10.3390/hemato3030027.
    10.3390/hemato3030027
  17. Ferreira, Bruna Velosa; Carneiro, Emilie Arnault; Pestana, Carolina; Barahona, Filipa; Caetano, Joana; Lopes, Raquel; Lúcio, Paulo; et al. "Patient-Derived Extracellular Vesicles Proteins as New Biomarkers in Multiple Myeloma - A Real-World Study". Frontiers in Oncology 12 (2022): http://dx.doi.org/10.3389/fonc.2022.860849.
    Acesso aberto • Publicado • 10.3389/fonc.2022.860849
  18. Ferreira, Bruna; Emilie Carneiro; Pestana, Carolina; Barahona, AF; Joana filipa caetano; Lucio, Paulo; Neves, Manuel; et al. "Extracellular vesicles protein cargo as new prognostic biomarker for Multiple Myeloma - a real-life observational study". Frontiers in oncology (2022):
    Submetido
  19. Emilie Arnault Carneiro; Filipa Barahona; Carolina Pestana; Cristina João. "Is Circulating DNA and Tumor Cells in Myeloma the Way Forward?". Hemato (2022): https://doi.org/10.3390/hemato3010006.
    10.3390/hemato3010006
  20. Bárbara B. Sousa; Rebelo de Almeida, Cátia; Ana Filipa Barahona Afonso; Lopes, Raquel; Ana Martins-Logrado; Cavaco, Marco; Neves, Vera; et al. "Selective inhibition of Brutons tyrosineyrosine kinase by a designed covalent ligand leads to potent therapeutic efficacy in blood cancers relative to clinically used inhibitors.". ACS Pharmacology and Translational Science (2022): 1-13. https://doi.org/10.1021/acsptsci.2c00163.
    Publicado • 10.1021/acsptsci.2c00163
  21. Lopes, Raquel; Caetano, Joana; Ana Filipa Barahona Afonso; Pestana, Carolina; Bruna Velosa Ferreira; Diana Lourenço; QUEIRÓS, ANA; et al. "Multiple myeloma-derived extracelular vesicles modulate the bone marrow immune microenvironment.". Frontiers in Immunology (2022): https://doi.org/10.3389/fimmu.2022.909880.
    Publicado
  22. Velosa Ferreira, Bruna; Arnault Carneiro, Emilie; Pestana, Carolina; Ana Filipa Barahona Afonso; Caetano, Joana; Lopes, Raquel; Lucio, Paulo; et al. "Patient-derived extracelullar vesicles proteins as new biomarkers in multiple myeloma: a real-world study". Frontiers in Oncology (2022): https://doi.org/10.3389/fonc.2022.860849..
    Publicado
  23. Lopes, Raquel; Ferreira, Bruna Velosa; Caetano, Joana; Barahona, Filipa; Carneiro, Emilie Arnault; João, Cristina. "Boosting Immunity against Multiple Myeloma". Cancers 13 6 (2021): 1221. http://dx.doi.org/10.3390/cancers13061221.
    Acesso aberto • Publicado • 10.3390/cancers13061221
  24. Moreau, Philippe; Kumar, Shaji K; San Miguel, Jesús; Davies, Faith; Zamagni, Elena; Bahlis, Nizar; Ludwig, Heinz; et al. "Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group". The Lancet Oncology 22 3 (2021): e105-e118. http://dx.doi.org/10.1016/s1470-2045(20)30756-7.
    Acesso aberto • Publicado • 10.1016/s1470-2045(20)30756-7
  25. Lopes, Raquel; Caetano, Joana; Ferreira, Bruna; Barahona, Filipa; Carneiro, Emilie Arnault; João, Cristina. "The Immune Microenvironment in Multiple Myeloma: Friend or Foe?". Cancers 13 4 (2021): 625. http://dx.doi.org/10.3390/cancers13040625.
    10.3390/cancers13040625
  26. Pestana, Carolina; SOUSA, LISETE; Arnault Carneiro, Emilie; Barahona, AF; Caetano, Joana; Lopes, Raquel (A71E-87C5-1CC5; Velosa Ferreira, Bruna; Cristina João. "Statistical methods for the study of extracellular vesicles content and their potential as biomarkers of multiple myeloma aggressiveness". Journal of Statistics on Health Decision 2 2 (2020): https://doi.org/10.34624/jshd.v2i2.19953.
    Publicado • 10.34624/jshd.v2i2.19953
  27. João, Cristina; Geraldes, Catarina; Neves, Manuel; Mariz, Mário; Trigo, Fernanda. "Management of older and frail patients with multiple Myeloma in the Portuguese routine clinical practice: Deliberations and recommendations from an expert panel of hematologists". Journal of Geriatric Oncology (2020): http://dx.doi.org/10.1016/j.jgo.2020.06.002.
    10.1016/j.jgo.2020.06.002
  28. Ferreira, Bruna; Caetano, Joana; Barahona, Filipa; Lopes, Raquel; Carneiro, Emilie; Costa-Silva, Bruno; João, Cristina. "Liquid biopsies for multiple myeloma in a time of precision medicine". Journal of Molecular Medicine (2020): http://dx.doi.org/10.1007/s00109-020-01897-9.
    10.1007/s00109-020-01897-9
  29. Almeida, Sílvia D.; Santinha, João; Oliveira, Francisco P. M.; Ip, Joana; Lisitskaya, Maria; Lourenço, João; Uysal, Aycan; et al. "Quantification of tumor burden in multiple myeloma by atlas-based semi-automatic segmentation of WB-DWI". Cancer Imaging 20 1 (2020): http://dx.doi.org/10.1186/s40644-020-0286-5.
    Publicado • 10.1186/s40644-020-0286-5
  30. Cristina João; Rui Bergantim; Manuel Neves; Sérgio Chacim; Celina Afonso; João Barradas; Manuela Bernardo; et al. "Multiple myeloma in elderly patients—a Portuguese multicentric real-life study". Annals of Hematology 98 7 (2019): 1689-1701. https://doi.org/10.1007/s00277-019-03640-y.
    10.1007/s00277-019-03640-y
  31. Richardson, P.G.; Oriol, A.; Beksac, M.; Liberati, A.M.; Galli, M.; Schjesvold, F.; Lindsay, J.; et al. "Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial". The Lancet Oncology 20 6 (2019): 781-794. http://www.scopus.com/inward/record.url?eid=2-s2.0-85067190733&partnerID=MN8TOARS.
    10.1016/S1470-2045(19)30152-4
  32. Hillengass, J.; Usmani, S.; Rajkumar, S.V.; Durie, B.G.M.; Mateos, M.-V.; Lonial, S.; Joao, C.; et al. "International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders". The Lancet Oncology 20 6 (2019): e302-e312. http://www.scopus.com/inward/record.url?eid=2-s2.0-85066247461&partnerID=MN8TOARS.
    10.1016/S1470-2045(19)30309-2
  33. Rb-Silva, R.; Goios, A.; Kelly, C.; Teixeira, P.; João, C.; Horta, A.; Correia-Neves, M.. "Definition of Immunological Nonresponse to Antiretroviral Therapy: A Systematic Review". Journal of Acquired Immune Deficiency Syndromes 82 5 (2019): 452-461. http://www.scopus.com/inward/record.url?eid=2-s2.0-85074875241&partnerID=MN8TOARS.
    10.1097/QAI.0000000000002157
  34. Cristina João; Vir Singh Negi; Michel D. Kazatchkine; Jagadeesh Bayry; Srini V. Kaveri. "Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies". The Journal of Immunology 200 6 (2018): 1957-1963. https://doi.org/10.4049/jimmunol.1701271.
    10.4049/jimmunol.1701271
  35. Rule S; Jurczak W; Jerkeman M; Rusconi C; Trneny M; Offner F; Caballero D; et al. "Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.". Leukemia (2018): http://europepmc.org/abstract/med/29572505.
    10.1038/s41375-018-0023-2
  36. Georg Hess; Simon Rule; Wojciech Jurczak; Mats Jerkeman; Rodrigo Santucci Silva; Chiara Rusconi; Dolores Caballero; et al. "Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus". Leukemia & Lymphoma 58 12 (2017): 2824-2832. https://doi.org/10.1080%2F10428194.2017.1326034.
    10.1080/10428194.2017.1326034
  37. Moreau P; Dimopoulos MA; Richardson PG; Siegel DS; Cavo M; Corradini P; Weisel K; et al. "Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.". European journal of haematology (2017): http://europepmc.org/abstract/med/28504846.
    10.1111/ejh.12903
  38. João C; Freitas J; Gomes F; Geraldes C; Coelho I; Neves M; Lúcio P; et al. "Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.". Annals of Hematology 95 6 (2016): 931-936. http://europepmc.org/abstract/med/27068406.
    Publicado • 10.1007/s00277-016-2662-6
  39. Barahona Afonso AF; João CM. "The Production Processes and Biological Effects of Intravenous Immunoglobulin.". (2016): http://europepmc.org/abstract/med/27005671.
    10.3390/biom6010015
  40. Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; et al. "Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.". (2016): http://europepmc.org/abstract/med/26673811.
    10.1016/S0140-6736(15)00667-4
  41. João C; Coelho I; Costa C; Esteves S; Lucio P. "Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center.". (2015): http://europepmc.org/abstract/med/25038919.
    10.1007/s00277-014-2164-3
  42. Carlos Costa; Cristina João; Inês Coelho; Maria João Vergueiro; Mafalda Ferreira; Maria Gomes da Silva; João C; et al. "Long-term Survival in Multiple Myeloma". Clinical Case Reports 2 5 (2014): 1-7. http://dx.doi.org/10.1001/archinte.1986.00360200217047.
    Publicado • 10.1002/ccr3.76
  43. Parreira J; Lúcio P; João C; Macedo A; Sarmento AB; Geraldes C; Gonçalves C; Esteves G. "Monoclonal gammopathies of indetermined significance: diagnosis and clinical follow-up guidelines". (2014): http://europepmc.org/abstract/med/25409226.
  44. Parreira, J.; Lúcio, P.; João, C.; Macedo, A.; Sarmento, A.B.; Geraldes, C.; Gonçalves, C.; Esteves, G.. "Monoclonal gammopathies of indetermined significance: Diagnosis and clinical follow-up guidelines,Gamapatias monoclonais de significado indeterminado: Critérios de diagnóstico e acompanhamento clínico". Acta Medica Portuguesa 27 5 (2014): 661-664. http://www.scopus.com/inward/record.url?eid=2-s2.0-84908397086&partnerID=MN8TOARS.
    10.20344/amp.5411
  45. Costa, N.; Pires, A.E.; Gabriel, A.M.; Goulart, L.F.; Pereira, C.; Leal, B.; Queiros, A.C.; et al. "Broadened T-cell repertoire diversity in ivIg-treated SLE patients is also related to the individual status of regulatory T-cells". Journal of Clinical Immunology 33 2 (2013): 349-360. http://www.scopus.com/inward/record.url?eid=2-s2.0-84879881255&partnerID=MN8TOARS.
    10.1007/s10875-012-9816-7
  46. Afonso, A.B.; Justo, L.N.; Queirós, A.C.; Fesel, C.; Cabral, M.S.; Da Silva, M.G.; Porrata, L.; et al. "Treatment with low doses of polyclonal immunoglobulin improves B cell function during immune reconstitution in a murine model". Journal of Clinical Immunology 33 2 (2013): 407-419. http://www.scopus.com/inward/record.url?eid=2-s2.0-84879888117&partnerID=MN8TOARS.
    10.1007/s10875-012-9802-0
  47. João, C.; Figueiredo, A.; Martins, H.F.. "Advantageous use of lenalidomide in multiple myeloma: Discussion of three case studies". Current Opinion in Oncology 24 SUPPL. 2 (2012): http://www.scopus.com/inward/record.url?eid=2-s2.0-84855934316&partnerID=MN8TOARS.
    10.1097/01.cco.0000410244.91697.5a
  48. Costa N; Pires AE; Gabriel AM; Goulart LF; Pereira C; Leal B; Queiros AC; et al. "Active regulatory T-cells contribute to broadened T-cell repertoire diversity in ivIg-treated SLE patients.". Journal of translational medicine (2011): http://europepmc.org/abstract/PMC/PMC3242290.
    10.1186/1479-5876-9-S2-P6
  49. Pires, A.E.; Afonso, A.F.; Queirós, A.; Cabral, M.S.; Porrata, L.; Markovic, S.N.; Kaveri, S.V.; Da Silva, M.G.; João, C.. "Treatment with polyclonal immunoglobulin during T-cell reconstitution promotes naive T-cell proliferation". Journal of Immunotherapy 33 6 (2010): 618-625. http://www.scopus.com/inward/record.url?eid=2-s2.0-77954956699&partnerID=MN8TOARS.
    10.1097/CJI.0b013e3181d3cb19
  50. João, C.; Farinha, P.; Da Silva, M.G.; Martins, C.; Crespo, M.; Cabeçadas, J.. "Cytogenetic abnormalities in MALT lymphomas and their precursor lesions from different organs. A fluorescence in situ hybridization (FISH) study". Histopathology 50 2 (2007): 217-224. http://www.scopus.com/inward/record.url?eid=2-s2.0-33846026333&partnerID=MN8TOARS.
    10.1111/j.1365-2559.2007.02580.x
  51. Cristina João. "Immunoglobulin is a highly diverse self-molecule that improves cellular diversity and function during immune reconstitution". Medical Hypotheses 68 1 (2007): 158-161. http://www.scopus.com/inward/record.url?eid=2-s2.0-33750738300&partnerID=MN8TOARS.
    10.1016/j.mehy.2006.05.062
  52. Joao, C.; Porrata, L.F.; Inwards, D.J.; Ansell, S.M.; Micallef, I.N.; Johnston, P.B.; Gastineau, D.A.; Markovic, S.N.. "Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma". Bone Marrow Transplantation 37 9 (2006): 865-871. http://www.scopus.com/inward/record.url?eid=2-s2.0-33646053849&partnerID=MN8TOARS.
    10.1038/sj.bmt.1705342
  53. João, C.; Ogle, B.M.; Geyer, S.. "Immunoglobulin promotes the diversity and the function of T cells". European Journal of Immunology 36 7 (2006): 1718-1728. http://www.scopus.com/inward/record.url?eid=2-s2.0-33746238425&partnerID=MN8TOARS.
    10.1002/eji.200635908
  54. João C; Ogle BM; Gay-Rabinstein C; Platt JL; Cascalho M. "B cell-dependent TCR diversification.". (2004): http://europepmc.org/abstract/med/15067046.
    10.4049/jimmunol.172.8.4709
  55. Ogle BM; Cascalho M; Joao C; Taylor W; West LJ; Platt JL; Ogle, B.M.; et al. "Direct measurement of lymphocyte receptor diversity.". Nucleic acids research 31 22 (2003): http://europepmc.org/abstract/med/14602932.
    10.1093/nar/gng139
  56. Cristina João; Malhadais N; Leite A.; Serra I.; Reves L.; Brandão, Tiago; Freitas, Paulo. "A case of Wegener‘s Granulomatosis". Revista Portuguesa Medicina Interna 3 (2001): 150-153.
    Publicado • 10.1002/art.11075
  57. João, Cristina. "Von Willebrand Disease". Revista Portuguesa Medicina Interna 1 (2001): 28-36.
    Publicado
  58. João, C.; Matias, T.; João C; Matias T; João, Cristina; Teresa Matias; João Sá,. "Paget's disease associated with myelofibrosis and myeloid metaplasia--a common pathophysiology ?". Haematologica 86 8 (2001): E22. http://www.scopus.com/inward/record.url?eid=2-s2.0-0035432117&partnerID=MN8TOARS.
    Publicado
Capítulo de livro
  1. João, Cristina. "Lymphomas". In The General and Family Medicine Manual. Portugal: Associação Portuguesa de Medicina Geral e Familiar, 2000.
    Publicado
Poster em conferência
  1. Caetano, Joana; Cristina João. "Characterizing the circulating immune cell populations in asymptomatic and symptomatic myeloma patients using high-dimensional spectral flow cytometry.". Trabalho apresentado em Annual Meeting of the Portuguese Society of Hematology, Viseu, Portugal, 2023.
  2. Caetano, Joana; Cristina João. "Characterizing the immune cell populations in asymptomatic and symptomatic myeloma patients using high-dimensional spectral flow cytometry". Trabalho apresentado em 12th ESLHO Symposium, Salamanca, Spain, 2023.
  3. Caetano, Joana; Cristina João. "Immune cell populations present in peripheral blood of asymptomatic and symptomatic myeloma patients". Trabalho apresentado em NOVA Research Week, Lisbon, Portugal, 2023.
  4. Caetano, Joana; Cristina João. "MRDeep Study: Measurable Residual Disease rates in patients with Multiple Myeloma who achieved complete response in 2nd or 3rd lines of treatment in Portugal.". Trabalho apresentado em 20th Annual IMS Meeting, Athens, Greece, 2023.
  5. Barahona, Filipa; Klein Wolterink, Roel; Galzerano, Antonio; Arnault Carneiro, Emilie; Caetano, Joana; Ferreira, Bruna Velosa; Queirós, Ana C.; Cristina João. "Multiple Myeloma and adjacent NK cells express the machinery to integrate neuronal signals". Trabalho apresentado em EHA2023 Hybrid Congress, 2023.
    10.1097/01.HS9.0000970252.77706.5e
  6. Caetano, Joana; Cristina João. "High-dimensional spectral cytometry characterization of the circulating immune cell profile of asymptomatic and symptomatic myeloma patients". Trabalho apresentado em EHA2023 Congress, Frankfurt, Germany, 2023.
  7. Caetano, Joana; Cristina João. "High-dimensional spectral cytometry characterization of the circulating immune cell profile of asymptomatic and symptomatic myeloma patients". Trabalho apresentado em 31th Sabatina de Hematología, Coimbra, Portugal, 2023.
  8. Lopes, Raquel; Diana Lourenço; Caetano, Joana; Ana Filipa Barahona Afonso; Velosa Ferreira, Bruna; QUEIRÓS, ANA; Arnault Carneiro, Emilie; Serre, Karine; Cristina João. "It takes two to tango: multiple myeloma and bone marrow immune cells". Trabalho apresentado em 16th ENII EFI EJI Summer School on Advanced Immunology, 2023.
  9. Cristina João; Caetano, Joana. "Measurable Residual Disease (MRD) assessment in the management of Multiple Myeloma (MM) in a real-world setting.". Trabalho apresentado em XVIII Congress of the Iberian Society of Cytometry, Madrid, Spain, 2023.
  10. Cristina João; Caetano, Joana. "Insights on how multiple myeloma-derived extracellular vesicles modulate the bone marrow niche". Trabalho apresentado em XLVIII Annual Meeting of the Portuguese Society of Immunology, Aveiro, Portugal, 2023.
  11. Ana Raquel lopes; Caetano, Joana; Ana Filipa Barahona; Velosa Ferreira, Bruna; Diana Lourenço; Ana C. Queirós; Matthiesen, Rune; et al. "Insights on how multiple myeloma-derived extracellular vesicles modulate the bone marrow immune niche". Trabalho apresentado em XLVIII Annual Meeting Portuguese Socienty of Immunology, 2023.
  12. Lopes, Raquel; Caetano, Joana; Ana Filipa Barahona Afonso; Velosa Ferreira, Bruna; Diana Lourenço; QUEIRÓS, ANA; Matthiesen, Rune; et al. "Insights on how multiple myeloma-derived extracellular vesicles modulate the bone marrow niche". Trabalho apresentado em XLVIII Annual Meeting Portuguese Society of Immunology, 2023.
  13. Francisco Silva; Lopes, Raquel; Ana Sofia Capacho; Maria Fortunato; Sofia Vaz; Oliveira, Francisco; Cristina João; Costa, Durval C.. ""In house" radiolabeling of anti-PD-L1 monoclonal antibodies with 111-Indium for in vivo imaging". Trabalho apresentado em EANM-23, 2023.
  14. Lopes, Raquel; Caetano, Joana; Ana Filipa Barahona Afonso; Pestana, Carolina; Velosa Ferreira, Bruna; Diana Lourenço; QUEIRÓS, ANA; et al. "Are you talking to me? How multiple myeloma-derived extracellular vesicles reprogramme the bone marrow immune niche". Trabalho apresentado em Champalimaud Research Symposium, 2022.
  15. Lopes, Raquel; Caetano, Joana; Ana Filipa Barahona Afonso; Pestana, Carolina; Velosa Ferreira, Bruna; Diana Lourenço; QUEIRÓS, ANA; et al. "Unraveling the crosstalk beterrn multiple myeloma and the bone marrow immune microenvironment: a role for myeloma-derived extracellular vesicles?". Trabalho apresentado em XV CAML V NeurULisboa PhD Students meeting, 2022.
  16. Lopes, Raquel; Caetano, Joana; Ana Filipa Barahona Afonso; Pestana, Carolina; Velosa Ferreira, Bruna; Diana Lourenço; QUEIRÓS, ANA; et al. "Multiple myeloma-derived extracellular vesicles induce an immunosuppressive bone marrow microenvironment". Trabalho apresentado em XLVII Annual Meeting Portuguese Society of Immunology, 2022.
  17. Nørgaard, Jakob Nordberg; Niels Abildgaard; Lysén, Anna; Tsykunova, Galina; Vangsted, Annette Juul; Cristina João; Remen, Nora; et al. "KRd Consolidation in Myeloma Patients with a Positive PET-CT after Standard First Line Treatment: A Phase II Study (CONPET)". Trabalho apresentado em The American Society of Hematology Annual Meeting & Exposition, Atlanta, USA, 2021.
  18. Pestana, Carolina; SOUSA, LISETE; Cristina João. Autor correspondente: Cristina João. "Study of biomarkers in Multiple Myeloma: a statistical approach for longitudinal assessment of extracellular vesicles and its prognostic value". Trabalho apresentado em 5.ª Conferência Anual da redeSAÚDE, 2021.
  19. Cláudia S. Constantino; Sónia Leocádio; Francisco Oliveira; Mariana Silva ; Carla Oliveira; Joana Castanheira; Ângelo Silva; et al. "Quantification of whole-body [18F]FDG avid lymphoma lesions: advantages of semiautomatic over manual segmentation. DOI: 10.1007/s00259-021-05547-1". Trabalho apresentado em European Association of Nuclear Medicine, 2021.
  20. Giovanni Palladini; Stefan Schönland; Giampaolo Merlini; Paolo Milani; Arnaud Jaccard; Frank Bridoux; Meletios A. Dimopoulos; et al. "Real-World Data on Patient Characteristics and Treatment Patterns for 3000 Patients with Systemic AL Amyloidosis in Europe between 2011 and 2018: A Retrospective Study by the European Myeloma Network". Trabalho apresentado em European Hematology Association Annual Meeting, 2021.
  21. Lopes, Raquel; Joana Filipa Braga de Jesus Caetano; Ana Filipa Barahona Afonso; Bruna Velosa Ferreira; Carolina Pestana; Emilie Carneiro; Cristina João; et al. "Immunosuppressive bone marrow microenvironment induced by multiple myeloma-derived extracellular vesicles". Trabalho apresentado em 2nd European Myeloma Network Meeting, 2021.
  22. Ana Martins-Logrado; Filipa Barahona; Vanda Póvoa; Cátia Almeida; Joana Caetano; Sónia Leocádio; Manuel Neves; et al. "Zebrafish "avatars" as a tool for personalized treatment of CLL patients.". Trabalho apresentado em Translational Research Conference on Chronic Lymphocytic Leukaemia Online, 2020.
  23. Carolina Pestna; SOUSA, LISETE; Emilie Carneiro; Ana Filipa Barahona; Joana Caetano; Ana Raquel lopes; Bruna Ferreira; Cristina João. "Statistical methods for the study of extracellular vesicles content and their potential as biomarkers of multiple myeloma aggressivenesshttps://proa.ua.pt/index.php/jshd/article/view/19953/15330". Trabalho apresentado em 2nd Statistics on Health Decision Making (SHDM): clinical trials, 2020.
  24. Raquel Lopes; Joana Caetano; Filipa Barahona; Bruna Velosa Ferreira; Jácome Toste; Catarina Ventura; Emilie Arnault Carneiro; Bruno Costa-Silva; Cristina João. "Immunosupressive Bone Marrow microenvironment via extracellular vesicles in multiple myeloma". Trabalho apresentado em Cancer Biology - From Basic to Translational Research, 2020.
  25. Lopes, Raquel; Joana Filipa Braga de Jesus Caetano; Ana Filipa Barahona Afonso; Bruna Velosa Ferreira; Emilie Carneiro; Jácome Toste; Catarina Ventura; et al. "Immunossupressive BM microenvironment via extracellular vesicles in Multiple Myeloma". Trabalho apresentado em Cancer Biology: From Basic to Translational Research, 2020.
  26. G. Palladini; G. Merlini; P. Milani; R. Hajek; R. Bergantim; Cristina João; S. Scho¨nland; et al. "Real World Management of Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study by European Myeloma Network". Trabalho apresentado em European Hematology Association Annual Meeting, 2020.
  27. Emilie Carneiro; Bruna Ferreira; Ana Filipa Barahona; joana Caetano; Raquel Lopes; Jácome Toste; Catarina Ventura; et al. "Extracellular vesicles proteins and their potential as biomarkers of multiple myeloma aggressiveness". Trabalho apresentado em Annual Meeting of Sociedade Portuguesa de Hematologia, Braga, Portugal, 2019.
  28. Ana Logrado; Vanda Póvoa; joana Caetano; Ana Filipa Barahona; Raquel Lopes; Sónia Leocádio; Manuel Neves; et al. "Zebrafish Avatars as a tool for personalized treatment of CLL patients - establishing a model". Trabalho apresentado em Annual Meeting of Sociedade Portuguesa de Hematologia, Braga, Portugal, 2019.
  29. Raquel Lopes; Bruna Ferreira; joana Caetano; Ana Filipa Barahona; Emilie Carneiro; Jácome Toste; Catarina Ventura; et al. "Exploring the bone marrow microenvironment communication via extracellular vesicles in multiple myeloma". Trabalho apresentado em Champalimaud Research Symposium 2019: Tissue Environment in Health and Disease, Lisbon, Portugal, 2019.
    10.1158/1538-7445.am2014-972
  30. Bruna Ferreira; Emilie Carneiro; Ana Filipa Barahona; Paulo Lúcio; Manuel Neves; Bruno Costa-Silva; Cristina João. "Exosomal Cargo in monoclonal gammopathies compared to healthy donors and its potential relation to myeloma aggressiveness". Trabalho apresentado em The 24th European Hematology Association Congress, Amesterdam, Netherlands, 2019.
  31. Bruna Ferreira; Paulo Lúcio; Manuel Neves; António Parreira; Bruno Costa-Silva; Cristina João. "Characterization of Circulating and Bone Marrow Derived Exosomes in Multiple Myeloma Patients". Trabalho apresentado em The American Society of Hematology Annual Meeting, San Diego, USA, 2018.
  32. Cristina João. "Absolute lymphocyte count and CD4 count predict a superior progression-free survival in non-Hodgkin’s lymphoma patients treated with rituximab and Interleukin-12". Trabalho apresentado em American Society of Hematology meeting, Atlanta, USA., 2015.
  33. João, Cristina; Carlos Costa (5913-6819-3D1E); Fernanda Trigo; Sergio Chacim; Paulo Lucio; Cristina Gonçalves; Ana Macedo. "ChatGPT Experience with the use of the MPT regimen in the treatment of patients with MM - Study by the Portuguese Multiple Myeloma Group". Trabalho apresentado em Annual Meeting of the Portuguese Society of Hematology, 2012.
  34. Sara Gomes; Carlos Costa (5913-6819-3D1E); João, Cristina; António Medina Almeida; Susana Carvalho; António Parreira. "Cryoglobulinemias, a common presence in various pathologies". Trabalho apresentado em Reunião Anual da Sociedade Portuguesa de Hematologia, Tróia, Portugal, 2010.
  35. Sara Gomes; Carlos Costa (5913-6819-3D1E); João, Cristina; António Medina Almeida; Susana Carvalho; António Parreira. "Basiodioboliomicose: diagnóstico diferencial de adenopatias: a propósito de um caso clínico". Trabalho apresentado em Reunião Anual da Sociedade Portuguesa de Hematologia, Tróia, Portugal, 2010.
  36. Lígia Justo; Barahona Afonso, Ana; Ana Queirós; Constantin Fesel; Ana Elisabete Pires; João, Cristina. "Immunoglobulin Treatment Improves Reconstitution of B Cell Compartment After Autologous Stem Cell Transplantation (ASCT)". Trabalho apresentado em Annual Meeting of the European Society of Hematology, Barcelona, Spain, 2010.
  37. Ana Filipa Barahona; Pires, Ana Elisabete; joana Caetano; Fátima Francisco; Maria Gomes da Silva; Cristina João. "Alterações imunológcas em doentes com Linfoma Não Hodgkin B (LNH B) induzidas pelo tratamento com poliquimioterapua e Rituximab". Trabalho apresentado em Annual Meeting of Sociedade Portuguesa de Hematologia, Tróia, Portugal, 2009.
  38. Ana Elisabete Pires; Salomé Cabral; Susana Esteves; Maria Gomes da Silva; Luís Porrata; Svetomir N. Markovic; Cristina João. "The effect of infusion of polyclonal immunoglobulin or its fragments in the improvement of the immune reconstitution after autologous stem cells transplantation (ASCT) in a murine model". Trabalho apresentado em American Society of Hematology Meeting, Atlanta, USA, 2007.
  39. Cristina João; Susan Geyer; Markovic, Svetomir; Morie Gertz, Martha Lacy; Angela Dispenzieri; Shagi Kumar; Suzanne Hayman; Luis F. Porrata. "Recovery of polyclonal immunoglobulin serum levels to normal levels after autologous stem cell transplantation predicts disease free survival in patients with multiple myeloma". Trabalho apresentado em American Society of Clinical Oncology meeting, Atlanta, USA., 2006.
  40. Cristina João; Luis F. Porrata; Ed Burgstaler; Wendy Neval; Cindy Uhl; Rajini Katipamula; Dennis A. Gastineau; Jeffrey Winters; Svetomir N. Markovic. "Immunologic autograft engineering by manipulation of apheresis machine collection settings". Trabalho apresentado em CIBMTR meeting, Hawaii, USA, 2006.
  41. Cristina João. "Early Lymphocyte Recovery after Autologous Stem Cell Transplantation Predicts Superior Survival in Mantle Cell Lymphoma". Trabalho apresentado em American Society of Hematology meeting, Atlanta, USA, 2005.
  42. Cristina João. "Recuperação Precoce do número total de linfocitos após transplante autólogo de precursores hematopoieticos prediz uma sobrevida superior em doentes com Linfoma do Manto". Trabalho apresentado em Annual Meeting of Sociedade Portuguesa de Hematologia, Espinho, Portugal, 2005.
  43. Cristina João. "TCR diversity and immune responses to transplants". Trabalho apresentado em Annual Meeting of Sociedade Portuguesa de Imunologia, Lisbon, Portugal, 2004.
  44. Cristina João. "TCR Diversity and the mounting of alloimmune response". Trabalho apresentado em American Transplantation Congress, Boston, USA., 2004.
  45. Cristina João. "Alterações citogenéticas numéricas em Linfomas MALT". Trabalho apresentado em Annual Meeting of Sociedade Portuguesa de Hematologia, Buçaco, Portugal, 2003.
  46. Cristina João. "B cell directed alloimmunity: a question revisited". Trabalho apresentado em American Transplantation Congress, Washington, USA., 2003.
  47. Cristina João. "Compatibility tests in patients with Warm-antibodies Autoimmune Hemolytic Anemia". Trabalho apresentado em I Simposium of Immunohematology, Porto, Portugal, 2001.
  48. Cristina João. "Primary Mediastinal Sclerosant Non-Hodgkin B Lymphoma: review of 7 cases from the Hematology Department of Francisco Gentil’s Portuguese Oncology Institute, Lisbon". Trabalho apresentado em 6th National Congress of Internal Medicine, Porto, Portugal, 2000.
Resumo em conferência
  1. Constantino, Cláudia; Oliveira, Francisco; Leocádio, Sónia; Silva, Mariana; Carla Oliveira; Castanheira, Joana; Silva, Angelo; et al. Autor correspondente: Constantino, Cláudia. "Deep learning-based fully automatic segmentation of whole-body [18F]FDG PET/CT images from lymphoma patients: addition of CT data has poor impact on networks performance". Trabalho apresentado em 36th Annual Congress of the European Association of Nuclear Medicine, Vienna, 2023.
    Publicado
  2. Cláudia S. Constantino; Sónia Leocádio; Francisco P. M. Oliveira; Mariana Silva; Carla Oliveira; Joana C. Castanheira; Ângelo Silva; et al. Autor correspondente: Cláudia S. Constantino. "Quantifcation of whole-body [18F]FDG avid lymphoma lesions: advantages of semiautomatic over manual segmentation". Trabalho apresentado em Annual Congress of the European Association of Nuclear Medicine, 2021.
    Publicado
  3. Rui, Bergantim; Cristina João; Catarina Geraldes; Manuel Neves; Fernanda Trigo; Mariana Neves; João Mendes; Hugo Pedrosa; Paulo Lúcio. "Multiple Myeloma in Portugal: Incidênce, Prevalence, Mortality and Treatment Pathern". Trabalho apresentado em European Hematology Association Anual Meeting, Frankfurt, 2020.
    Publicado
  4. Manuel Neves; Fernanda Trigo; Rui Bergantim; Cristina João; Paulo Lúcio; Mariana Neves; João Mendes; et al. "Multiple Myeloma in Portugal: Burden of Disease and Cost if Illness". Trabalho apresentado em European Hematology Association Annual Meeting, Frankfurt, 2020.
    Publicado • 10.1007/s40273-020-00993-5

Outros

Outra produção
  1. "VOLTA" Project. A programme to train clinical teams at Vilanculo Regional Hospital in Mozambique with the means, equipment and training for point-of-care ultrasound diagnosis in various clinical contexts, such as trauma or infection.. 2023. Cristina João; Carlos Costa. https://www.gofundme.com/f/projeto-volta.
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2023/05/13 Multiple Myeloma and adjacent NK cells can express the machinery to integrate neuronal signals 31st Sabbath in Hematology
Centro Hospitalar da Universidade de Coimbra (Coimbra, Portugal)
2021/12/11 Systemic light chain amyloidosis across Europe: Key outcomes from a retrospective study of 4500 patients The American Society of Hematology Annual Meeting & Exposition, Atlanta, USA
American Society of Hematology (Atlanta, Estados Unidos)
2020/10/12 First glimpse on real-world efficacy outcomes for 2000 patients with systemic light chain amyloidosis in Europe: a retrospective observational multicenter study by the european myeloma network. American Society of Hematology meeting
(Estados Unidos)
2020/02/12 Statistical methods for the study of extracellular vesicles content and their potencial as biomarkers of multiple myeloma aggressiveness iMed Conference
Universidade Nova de Lisboa Faculdade de Ciências Médicas (Lisboa, Portugal)
2016/11 Treatment of Multiple Myeloma old patients - a Portuguese multicentric real-life study Annual Meeting of the Portuguese Society of Hematology
Portuguese Society of Hematology (Povoa do Varzim, Portugal)
2014 New therapies in Hemato-oncology Immunotherapy and intra cellular signaling inhibition Annual Meeting of the Portuguese Society of Human Genetics
Portuguese Society of Human Genetics
2012/11/10 Lenalidomide in the treatment of relapsed/refractory Multiple Myeloma - Importance of early treatment on overall survival Annual meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Porto, Portugal)
2012/10/10 Respiratory amyloidosis, from surprise to panic XXVIII Pulmonology Congress
Sociedade Portuguesa de Pneumologia (Tróia, Portugal)
2012/01/26 Monoclonal gammopathies - From biology to treatment Atualizações em Oncologia 2012, 26ª Reunião - 1º Congresso do Cimago
Linha de Investigação Clínica e Interdisciplinar em Meio Ambiente, Genética e Oncobiologia (Coimbra, Portugal)
2011/11/11 Treatment with low-dose polyclonal immunoglobulin improves B lymphocyte cell function during immune reconstitution. Anual Meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Albufeira, Portugal)
2010/11/12 MPT as first-line treatment in multiple myeloma patients not eligible for transplant: a Portuguese multicenter study Anual meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Tróia, Portugal)
2009 A decade of thalidomide use in multiple myeloma patients - Experience from the Hematology Department of IPOFG, Lisbon Jornadas do ROR Sul
Registo Oncológico Regional (Lisboa, Portugal)
2009 Immunological interdependencies between B and T lymphocytes “Manuela Correia lecture”, Annual Meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Tróia, Portugal)
2008/11/14 Treatment with immunoglobulin or molecule fragments after hematopoietic precursor transplantation increases peripheral cell proliferation Anual Meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Torres Vedras, Portugal)
2007/11/10 Effect of immunoglobulin or its derivatives infusion on immune reconstitution after autologous hematopoietic stem cell transplantation (ASCT) in an animal model (mouse) Anual Meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Albufeira, Portugal)
2007 Treatment with polyclonal immunoglobulin and its fragments optimize recovery of IgM serum levels after autologous stem cells transplantation (ASCT) Reunião Anual da Sociedade Portuguesa de Imunologia
Sociedade Portuguesa de Imunologia (Lisboa, Portugal)
2007 Immune reconstitution after autologous stem cell transplantation Scientific meeting
Unidade de Investigação em Patobiologia Molecular, Francisco Gentil’s - Portuguese Oncology Institute (Lisboa, Portugal)
2005/04 Immunoglobulin Heavy Chain and the life of Memory B cells - Abstract 47.2 FASEB Research Conference - American Society of Immunology Meeting
Federation of American Societies for Experimental Biology (san Diego, Estados Unidos)
2005 Survival of B Cells Lacking Surface Ig Keystone B cells Meeting
(Colorado, Estados Unidos)
2004/12 Driving T cell development in the thymus, abstract # 3860 American Society of Hematology meeting, 2004, San Diego, USA.
American Society of Hematology (San Diego, Estados Unidos)
2004/11 Impact of B lymphocytes on T lymphocyte development Annual Meeting of Sociedade Portuguesa de Hematologia
Sociedade Portuguesa de Hematologia (Portugal)
2004/06 A new road to T cell diversification 9th Congress of the European Hematology Association
European Hematology Association (Genebra, Suiça)
2004/05 T cell repertoire expansion by B cells and immunoglobulin American Transplantation Congress Annual Meeting
American Transplantation Congress (Boston, Estados Unidos)
2004/04 B cells directed-T cell development American Society of Immunology Meeting, FASEB 2004
FASEB (Washington, D.C., Estados Unidos)
2004 Heavy chain promotes positive selection of CD4 T cells Annual Meeting of the Portuguese Society of Immunology
Portuguese Society of Immunology (Lisbon, Portugal)
2004 TCR diversity and immune responses to transplantation Transplant Grand Rounds
Mayo Clinic (Rochester, Estados Unidos)
2003/05 Delayed rejection of male to female skin grafts by memory like T cells American Transplantation Congress, 2003, Washington, D.C., USA.
American Transplantation Congress, (Washington, D.C., Estados Unidos)
2002 NK cell non’Hodgkin Lymphoma: A clinico-pathology entity of the Middle line Lethal Granuloma – clinical case XV National Meeting of ENT and Cervico-Facial Surgery
National Society of ENT and Cervico-Facial Surgery (Aveiro, Portugal)
2001 Anemia and Dyserythropoiesis - CDA II XIV Sabatin of Hematology, Coimbra Hospital Center, 2001
Centro Hospitalar e Universitário de Coimbra (Coimbra, Portugal)
2000 A case of Adult’s Still Disease Intensive Care Portuguese Society Annual Simposum/First Santarém’s Congress of Intensive Care
Intensive Care Portuguese Society (Santarém, Portugal)
2000 Paget’s Bone Disease associated with Myelofibrosis with Myeloid Metaplasia 6th National Congress of Internal Medicine
National Congress of Internal Medicine (Porto, Portugal)
1999/11 Review of 6 cases of Kikushi-Fugimoto Disease Annual Meeting of the Portuguese Society of Hematology
Portuguese Society of Hematology (Estoril, Portugal)

Orientação

Título / Tema
Papel desempenhado
Curso (Tipo)
Instituição / Organização
2020/11/09 - Atual Integration of neuronal signals by tumour-infiltrating natural killer and myeloma cells - NeuriMM
Orientador de Ana Filipa Barahona Afonso Tavares Cardoso
PhD in Biomedicine (Doutoramento)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2020/09/14 - Atual Combined GEnetic and immuNe signatures associated with depth of response and Outcome in MultiplE Myeloma.
Orientador de Joana Filipa de Jesus Caetano
PhD in Health Sciences (Doutoramento)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2021/01/01 - 2025/12/31 Combined immunotherapeutic approach for targeting bone marrow microenvironment in Multiple Myeloma.
Orientador de Ana Raquel Vicente Lopes
Programa Doutoral do Centro Académico de Medicina de Lisboa (ramo de Medicina; ramo de Ciências Biomédicas; ramo de Ciências e Tecnologias da Saúde) (Doutoramento)
Universidade de Lisboa Faculdade de Medicina, Portugal
2019/09/01 - 2021/03/31 Statistical methods for the study of extracellular vesicles content and their potential as biomarkers of multiple myeloma aggressiveness.
Coorientador de Carolina Festas Pestana
Bioestatística (Mestrado)
Universidade de Lisboa Faculdade de Ciências, Portugal
2020/01/13 - 2020/02/21 Internship integrated in the Discipline of Introductory Program to Professional Practice
Coorientador
Ciências de Engenharia Biomédica (Iniciação científica)
Universidade Nova de Lisboa Faculdade de Ciências e Tecnologia, Portugal
2019/03/01 - 2019/06/30 Research Project Discipline integrated in curriculum of the Bachelor in Medicine.
Orientador de Madalena Teixeira Santos de Sousa Gonçalves,
Medicina (Iniciação científica)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2016 - 2019 Thymic function and regulatory T cells in the immune recovery of HIV infected patients. Funding FCT: PD/BD/106047/2015
Coorientador de Rita Ribeiro da Silva
Medicina (Doutoramento)
Universidade do Minho, Portugal
2017 - 2018 Atlas-based semi-automatic segmentation of Whole-Body DWI Images: Quantification of tumour burden
Coorientador de Silvia Alexandra Dias Almeida
Ciências de Engenharia Biomédica (Mestrado)
Universidade Nova de Lisboa Faculdade de Ciências e Tecnologia, Portugal
2017 - 2017 The role of metastatic microenvironment in Multiple Myeloma extramedullary disease. Funding FCT: PTDC/MEC-HEM/30315/2017
Orientador de Bruna Velosa Ferreira
Medicina (Doutoramento)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2017 - 2017 B cells modulation of T cells' function and repertoire: immune characterization of Non Hodgkin Lymphoma patients receiving chemotherapy, with or without the CD20 monoclonal antibody, Rituximab. Funding Associação Portuguesa Contra a Leucemia: APCL 2006-30.4M.AP/MJ
Orientador
Bioquímica (Mestrado)
Universidade de Évora Escola de Ciências e Tecnologia, Portugal

Organização de evento

Nome do evento
Tipo de evento (Tipo de participação)
Instituição / Organização
2023/03/18 - Atual Member of the scientific and organizing committee of the "First National Meeting on Multiple Myeloma". (2023/03/18)
Seminário (Membro da Comissão Científica)
Sociedade Portuguesa de Hematologia, Portugal
2021/09/01 - Atual Champalimaud Foundation Scientific Research Colloquium (2023/09/01)
Seminário (Coorganizador)
Fundação Champalimaud, Portugal
2021/03/24 - 2021/03/24 Workshop: Sex and Gender Dimension in Your Research (2021/03/24 - 2021/03/24)
Mesa-redonda (Coorganizador)
Fundação Champalimaud, Portugal

Participação em evento

Descrição da atividade
Tipo de evento
Nome do evento
Instituição / Organização
2023/03/18 - Atual Speaker at the First National Meeting on Multiple Myeloma about "1st line treatment in multiple myeloma"
Encontro
First National Meeting on Multiple Myeloma
Sociedade Portuguesa de Hematologia, Portugal
2016/11/11 - Atual Invited speaker at the round table on "Immunotherapy": Lecture entitled "Immune mechanisms and intervention possibilities", Lisbon, Portugal
Encontro
3º ABC em Imunologia para Médicos, Fundação Calouste Gulbenkian
Hospital CUF Descobertas, Portugal
2016/10/08 - Atual Invited speaker in "Focusing on Remission in Multiple Myeloma" (Celgene Satellite Symposium), Milan, Italy
Conferência
3rd International Conference on Multiple Myeloma
European School of Hematology, França
2016/02/12 - Atual Invited speaker on "New imaging strategies for diagnosis and staging on Multiple Myeloma and Lymphoma", Lisbon, Portugal
Simpósio
first ESOR/Champalimaud Foundation Symposium on “Imaging Hallmarks of Cancer”
Fundação Champalimaud, Portugal
2015 - Atual Invited speaker in Immunology meeting entitled "Mecanismos Imunes e possibilidades de intervenção", Oeiras, Portugal
Mesa-redonda
ABC em Imunologia - Imunoterapia
Instituto Gulbenkian de Ciência, Portugal
2015 - Atual Invited speaker in "Novas abordagens da LLC- ibrutinib"
CUF Infante Santo Hospital, Portugal
2022/11/10 - 2022/11/12 Speaker on "Emotional adjustment of the person with hemato-oncologic disease" at the round table entitled "Multidimensionality: Caring for the person with hemato-oncologic disease".
Mesa-redonda
Annual Meeting 2022
Sociedade Portuguesa de Hematologia, Portugal
2022/11/10 - 2022/11/12 Speaker at the Satellite Symposium on "BLENREP - Innovation in MM treatment: From studies to clinical practice".
Simpósio
Anual meeting 2022
Sociedade Portuguesa de Hematologia, Portugal
2021/10/06 - 2021/11/30 Invited Speaker at the Online Course Actualización en onconefrología organized by "La Sociedad Latinoamericana de Nefrología e Hipertensión (SLANH)" with the educational, IT and logistical management of EviMed. Módulo 5: Paraproteínas & Enfermedad Renal. Talk: Principios y novedades de la terapia anti-neoplásica en la GMSR https://redemc.net/campus/wp-content/uploads/2021/10/Programa-OncoNefro-ES_Campus-1.pdf
Outro
Online Course "Actualización en Onconefrología/ Update in Onconephology"
EviMed Research Group LLC, Estados Unidos
2021/11/11 - 2021/11/13 Invited Speaker at the Portuguese Society f Hematology Annual Meeting - Binding Site Symposium.: "Tecnologias inovadoras no diagnóstico e seguimento de precisão do Mieloma Múltiplo /Novel technologies to diagnose and monitor Multiple Myeloma"
Encontro
Reunião Anual SPH 2021
Sociedade Portuguesa de Hematologia, Portugal
2021/11/01 - 2021/11/13 Invited Speaker at the Portuguese Society of Hematology Annual Meeting - Conference on the Educational Program: "Maintenance treatment for Multiple Myeloma".
Encontro
Portuguese Society of Hematology Annual Meeting 2021
Sociedade Portuguesa de Hematologia, Portugal
2018/07/18 - 2018/07/21 Invited chairwoman at the ARVO-Champalimaud Foundation Ocular Oncogenesis & Oncology, Lisbon, Portugal
Conferência
Ocular Oncogenesis & Oncology
Arvo Foundation for Eye Research, Estados Unidos

Fundação Champalimaud, Portugal
2016/10/28 - 2016/10/29 Invited speaker in ASKLEPIOS Course, Lisbon, Portugal
Simpósio
SYMPOSIUM ON IMAGING HALLMARKS OF CANCER – ESOR
Fundação Champalimaud, Portugal

European School of Radiology, Áustria
2016/09/22 - 2016/09/23 Invited speacker in "Hematology Masterclass", Budapest, Hungary
Seminário
Hematology Medical Education Program
Janssen-Cilag Kft, Hungria
2016/02/08 - 2016/02/19 Invited speaker in a Hematology Debate Meeting, Vienna, Austria
Encontro
Hematology Medical Education Program
Janssen-Cilag Pharma GmbH, Áustria
2016 - 2016 Invited speaker with lecture presentation: "New approaches from LLC- ibrutinib", Lisbon, Portugal
Conferência
7ª Reunião Anual da Associação Portuguesa de Farmácias Hospitalares, 2016
Associação Portuguesa de Farmácias Hospitalares, Portugal
2014 - 2014 Invited speaker with the titel "New therapies in Hemato-oncology and Immunotherapy and intra cellular signaling inhibition", Lisbon, Portugal
Simpósio
2014 Annual Meeting of the Portuguese Society of Human Genetics
Sociedade Portuguesa de Genética Humana, Portugal

Júri de grau académico

Tema
Tipo de participação
Nome do candidato (Tipo de grau)
Instituição / Organização
2023/11/22 Understanding the Role of Flower Code in Tumorigenesis
Vogal
Dénise dos Reis da Rosa de Azevedo Camacho (Doutoramento)
Universidade Nova de Lisboa Instituto de Tecnologia Química e Biológica António Xavier, Portugal

Arbitragem científica em conferência

Nome da conferência Local da conferência
2024/03/01 - 2024/06/12 European Haematology Association Annual Meeting (EHA2024 Hybrid Congress - Myeloma and other Monoclonal gammopathies) Madrid, Spain
2022/03/03 - 2022/03/14 European Haematology Association Annual Meeting (EHA2022 Hybrid Congress) Vienna

Arbitragem científica em revista

Nome da revista (ISSN) Editora
2021/10/13 - Atual Cancers (2072-6694) MDPI
2017/01/01 - Atual Cancers (2072-6694) IMDP
2017/01/01 - Atual International Journal of Molecular Sciences (1422-0067) IMDP
2017/01/01 - Atual Clinical Case Reports (2050-0904) John Wiley & Sons Ltd
2017/01/01 - Atual OncoTargets and Therapy (1178-6930) Dove Medical Press Ltd

Comissão de avaliação

Descrição da atividade
Tipo de assessoria
Instituição / Organização Entidade financiadora
2021/03/01 - Atual External Reviewer, PhD Scholarship call, FCT, PT
Avaliador
Fundação para a Ciência e a Tecnologia, Portugal Fundação para a Ciência e a Tecnologia
2015 - Atual Member of the Examination Jury for a position of specialist in clinical hematology at Centro Hospitalar do Algarve
Avaliador
Centro Hospitalar do Algarve EPE, Portugal

Curso / Disciplina lecionado

Disciplina Curso (Tipo) Instituição / Organização
2023/04/11 - Atual Cancer immunotherapy - a global overview and clinical relevance Doctoral Programme in Health Sciences - 14th edition (Doutoramento) Universidade de Coimbra Faculdade de Medicina, Portugal
2023/02/23 - 2023/02/25 Immunology as a basis in the fight against multiple myeloma. Perspectives in Hematology (Outros) DNA Prime - Scientific Education, Portugal
2016 - 2021/04 Invited Professor of the Doctoral Program in Health Sciences - Oncobiology and Cancer Course Curso de Oncobiologia e Cancro (Doutoramento) Universidade de Coimbra Faculdade de Medicina, Portugal
2010 - 2020 Professor of Immunology Medicina Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2016/02/08 - 2016/02/19 Hematology Debate Meeting, Hematology Medical Education Program Hematology Medical Education (Postgraduate Certificate) Janssen-Cilag Pharma GmbH, Áustria

Entrevista / Programa (rádio / tv)

Programa Tema
2023/04/03 - Atual Médico da Casa /House Physician Multiple Myeloma
2023/02/04 - Atual CNN Sábado World Cancer Day is celebration (February 4th). The evolution in cancer therapies that have allowed a higher survival rate and a better quality of life for those diagnosed.
2019/03/07 - Atual Guest speaker in the tv programme "Edição da Manhã" (SIC) Multiple Myeloma
2014/10/22 - Atual Guest speaker in the tv programme "Bom dia Portugal" (RTP) Multiple Myeloma

Membro de associação

Nome da associação Tipo de participação
2016 - Atual International Myeloma Foundation Membro activo
2014 - Atual International Multiple Myeloma Working Group Membro activo
2009 - Atual European Hematology Association Membro activo
2000 - Atual Portuguese Society of Hematology Membro activo
1994 - 1994 Students Association of the Faculty of Medicine of University of Lisbon

Membro de comissão

Descrição da atividade
Tipo de participação
Instituição / Organização
2023/05/01 - Atual Board Member of the EuroFlow Consortium
Membro
EuroFlow, Países Baixos
2020/12/22 - 2020/12/22 Member of the jury for a doctoral thesis project in the Doctoral Program in Health Sciences at the University of Coimbra
Membro
Universidade de Coimbra, Portugal
1994 - 1995 Elected member of the Senate of the University of Lisbon
Membro

Tutoria

Tópico Nome do aluno
2019/08/19 - 2020/01/22 Short term internship Catarina Ventura
2019/07/08 - 2019/08/31 Summer Internship Jácome Toste
Distinções

Prémio

2023 Women in Science
Ciência Viva, Portugal
2022 Prize José Eduardo Guimarães - Best work in Hematology
2020 Award Innovate Competition; iMed Conference 13,0
Universidade Nova de Lisboa, Portugal
2019 Giled Génese
Gilead Sciences Lda, Portugal
2004 Young Hematologist Award, Portuguese Society of Hematology
Sociedade Portuguesa de Hematologia, Portugal

Título

2018 Consultant in Hematology
ACSS- Administração Central do Sistema de Saude, Portugal

Outra distinção

2011 Best Experimental Work
Sociedade Portuguesa de Hematologia, Portugal
2009 2º Best Experimental Work - Poster
Sociedade Portuguesa de Hematologia, Portugal
2003 1º Best Experimental Work - Poster
Sociedade Portuguesa de Hematologia, Portugal
2003 Travel Award
American Association of nephrology, Estados Unidos